Supplementary Data. Correlation analysis. Importance of normalizing indices before applying SPCA
|
|
- Avice Chase
- 5 years ago
- Views:
Transcription
1 Supplementary Data Correlation analysis The correlation matrix R of the m = 25 GV indices calculated for each dataset is reported below (Tables S1 S3). R is an m m symmetric matrix, whose entries r ij = r ji represent the correlation among the i-th and j-th elements of the vector collecting all GV indices; the diagonal entries of the correlation matrix R are equal to 1, quantifying the correlation between a GV index and itself. Results obtained in the three cases are consistent with the correlation values documented in the literature Importance of normalizing indices before applying SPCA Normalizing GV indices before applying SPCA is key to avoiding the possibility that the heterogeneity of their scale (e.g.,,, and have numerical values larger than,, and Hypoglycemic Index) may influence the results. For instance, without normalization, results of SPCA would change when glucose concentration is measured in mmol/l (Table S4, right columns) rather than in mg/ dl (Table S4, left columns), simply because some indices (such as,,, and ) decrease their values by 18 times when converting from mg/l to mmol/l.
2 Supplementary Table S1. Dataset 1 (17 Continuous Glucose Monitoring Time-Series) w dm w dm M , Average Daily Risk Range;, Blood Glucose Risk Index;, percentage coefficient of variation;, Glycemic Risk Assessment Diabetes Equation;,, and, percentages of score due to euglycemia, hypoglycemia, and hyperglycemia, respectively;, High Blood Glucose Index;, Hyperglycemic Index;, Hypoglycemic Index;, Index of Glucose Control;, Interquartile Range;, Low Blood Glucose Index;, Mean Amplitude of Glycemic Excursions; dm, of daily s; w, of daily s (within-day variability);,, and, percentage of values in target, below target, and above target, respectively.
3 Supplementary Table S2. Dataset 2 (16 Continuous Glucose Monitoring Time-Series) w dm w dm M , Average Daily Risk Range;, Blood Glucose Risk Index;, percentage coefficient of variation;, Glycemic Risk Assessment Diabetes Equation;,, and, percentages of score due to euglycemia, hypoglycemia, and hyperglycemia, respectively;, High Blood Glucose Index;, Hyperglycemic Index;, Hypoglycemic Index;, Index of Glucose Control;, Interquartile Range;, Low Blood Glucose Index;, Mean Amplitude of Glycemic Excursions; dm, of daily s; w, of daily s (within-day variability);,, and, percentage of values in target, below target, and above target, respectively.
4 Supplementary Table S3. Dataset (33 Continuous Glucose Monitoring Time-Series) w dm w dm J - index M , Average Daily Risk Range;, Blood Glucose Risk Index;, percentage coefficient of variation;, Glycemic Risk Assessment Diabetes Equation;,, and, percentages of score due to euglycemia, hypoglycemia, and hyperglycemia, respectively;, High Blood Glucose Index;, Hyperglycemic Index;, Hypoglycemic Index;, Index of Glucose Control;, Interquartile Range;, Low Blood Glucose Index;, Mean Amplitude of Glycemic Excursions; dm, of daily s; w, of daily s (within-day variability);,, and, percentages of values in target, below target, and above target, respectively.
5 Supplementary Table S4. Example of How the Lack of Indices Normalization Can Lead to Inconsistencies in the Results Dataset, PC 1 PC 2 Dataset 1 (81%) Dataset 1 (91%) Dataset 2 (62%) Dataset 2 (73%) Dataset (60%) Dataset (83%) In particular, glycemic variability indices selected by sparse principal component (PC) for each PC for datasets 1, 2, and are reported. Results change when glycemic variability indices are derived from continuous glucose monitoring time-series expressed in mmol/l (right columns) rather than in mg/dl (left columns)., Average Daily Risk Range;, Blood Glucose Risk Index;, percentage coefficient of variation;,, and, percentages of Glycemic Risk Assessment Diabetes Equation score due to euglycemia, hyperglycemia, and hypoglycemia, respectively;, High Blood Glucose Index;, Index of Glucose Control;, Low Blood Glucose Index;, Mean Amplitude of Glycemic Excursions.
CareLink. software REPORT REFERENCE GUIDE. Management Software for Diabetes
CareLink Management Software for Diabetes software REPORT REFERENCE GUIDE How to use this guide Each type of CareLink report and its components are described in the following sections. Report data used
More informationReport Reference Guide
Report Reference Guide How to use this guide Each type of CareLink report and its components are described in the following sections. Report data used to generate the sample reports was from sample patient
More informationAPPENDIX American Diabetes Association. Published online at
APPENDIX 1 INPATIENT MANAGEMENT OF TYPE 2 DIABETES No algorithm applies to all patients with diabetes. These guidelines apply to patients with type 2 diabetes who are not on glucocorticoids, have no
More informationHypoglycemia Reassessment at Orange Regional Medical Center
What is the Society of Medicine s Glycemic Control equips Program? The Society of Medicine s (SHM s) Glycemic Control Electronic Quality Improvement Program (GC equips) assists with optimizing glycemic
More informationTHERAPY MANAGEMENT SOFTWARE FOR DIABETES
THERAPY MANAGEMENT SOFTWARE FOR DIABETES Report Report Interpretation Reference Guide Guide 2007 Medtronic MiniMed. All rights reserved. 6025274-0U2 120707 CareLink Pro Report Reference Guide 0 p.2 Sensor
More informationReport Reference Guide. THERAPY MANAGEMENT SOFTWARE FOR DIABETES CareLink Report Reference Guide 1
Report Reference Guide THERAPY MANAGEMENT SOFTWARE FOR DIABETES CareLink Report Reference Guide 1 How to use this guide Each type of CareLink report and its components are described in the following sections.
More informationOneTouch Reveal web app Report Reference Guide
OneTouch Reveal web app Report Reference Guide Your step-by-step guide to setting up and using the OneTouch Reveal web app OneTouch Verio meter OneTouch Verio Flex meter OneTouch Verio IQ meter OneTouch
More informationTHERAPY MANAGEMENT SOFTWARE FOR DIABETES
THERAPY MANAGEMENT SOFTWARE FOR DIABETES Report Report Interpretation Reference Guide Guide 2009 Medtronic MiniMed. All rights reserved. 6025274-012_a CareLink Pro Report Reference Guide 0 p.2 Adherence
More informationGlycemic Variability:
Glycemic Variability: Do the Differences Make a Difference? Kim L Kelly, PharmD, BCPS, FCCP Define Variability VERY LOW GLYCEMIC VARIABILITY LOW GLYCEMIC VARIABILITY HIGH GLYCEMIC VARIABILITY So what s
More informationGlycemic Control IU Health Diabetes Centers
Glycemic Control IU Health Diabetes Centers Central Nursing Orientation 3/10/2014 1 Objectives Identify laboratory results that diagnosis diabetes and reflect glycemic control Describe glycemic control
More informationDIABETES MANAGEMENT DISCHARGE COMMUNICATION (DM-DC) AUDIT TOOL
DIABETES MANAGEMENT DISCHARGE COMMUNICATION (DM-DC) AUDIT TOOL Facility: Date: Data Collector s name: Email/Phone: Purpose: To evaluate your facility practices regarding communication of requisite diabetes
More informationApril Dear (Editor):
April 2014 Dear (Editor): Registered Dietitians (RD) play an integral role in patient care in the medical intensive care unit. RD s have increased knowledge in blood glucose control and reducing adverse
More informationClinical Value and Evidence of Continuous Glucose Monitoring
Clinical Value and Evidence of Continuous Glucose Monitoring 9402313-012 Objective To review the clinical value and the recent clinical evidence for Professional and Personal CGM Key Points CGM reveals
More informationGLYCEMIC CONTROL IN NEUROCRITICAL CARE PATIENTS
GLYCEMIC CONTROL IN NEUROCRITICAL CARE PATIENTS David Zygun MD MSc FRCPC Professor and Director Division of Critical Care Medicine University of Alberta Zone Clinical Department Head Critical Care Medicine,
More informationCSE 255 Assignment 9
CSE 255 Assignment 9 Alexander Asplund, William Fedus September 25, 2015 1 Introduction In this paper we train a logistic regression function for two forms of link prediction among a set of 244 suspected
More informationPosition Statement of ADA / EASD 2012
Management of Hyperglycemia in Type2 Diabetes: A Patient- Centered Approach Position Statement of ADA / EASD 2012 Cause of : Type 2 diabetes Cardiovascular disorders Blindness End-stage renal failure Amputations
More informationDiabetes Care 32: , for achieving euglycemia in type 1 diabetes
Clinical Care/Education/Nutrition/Psychosocial Research O R I G I N A L A R T I C L E The Effect of Continuous Glucose Monitoring in Well-Controlled Type 1 Diabetes JUVENILE DIABETES RESEARCH FOUNDATION
More informationControl of Glycemic Variability for Reducing Hypoglycemia Jae Hyeon Kim
Control of Glycemic Variability for Reducing Hypoglycemia Jae Hyeon Kim Division of Endocrinology and Metabolism, Samsung Medical Center, Sungkyunkwan University School of Medicine Conflict of interest
More informationUsefulness of Ambulatory Glucose Profile (AGP) in Diabetes Care
C H A P T E R 41 Usefulness of Ambulatory Glucose Profile (AGP) in Diabetes Care K Chaithanya Murthy, B Ramya, E Vidya, RM Anjana, V Mohan ABSTRACT Over the past decades, several newer technologies have
More informationNorbert Hermanns, PhD 1,2, Beatrix Schumann, MD 2, Bernhard Kulzer, PhD 1,2, and Thomas Haak, MD 1,2. Original Article
524105DSTXXX10.1177/1932296814524105Journal of Diabetes Science and TechnologyHermanns et al research-article2014 Original Article The Impact of Continuous Glucose Monitoring on Low Interstitial Glucose
More informationEmanuele Bosi dichiara di aver ricevuto negli ultimi due anni compensi o finanziamenti dalle seguenti Aziende Farmaceutiche e/o Diagnostiche:
Emanuele Bosi dichiara di aver ricevuto negli ultimi due anni compensi o finanziamenti dalle seguenti Aziende Farmaceutiche e/o Diagnostiche: - Abbott - Roche - Takeda - Novartis - Astra Zeneca - Medtronic
More informationMultiplicative Surrogate Standard Deviation A Group Metric for the Glycemic Variability of Individual Hospitalized Patients
Multiplicative Surrogate Standard Deviation A Group Metric for the Glycemic Variability of Individual Hospitalized Patients Susan S. Braithwaite, M.D. Visiting Clinical Professor, University of Illinois
More information10.4.a. Optimal glucose control: Insulin therapy March 2013
10.4.a. Optimal glucose control: Insulin therapy March 2013 2013 Recommendation: Based on 26 level 2 studies, we recommend that hyperglycemia (blood sugars > 10 mmol/l) be avoided in all critically ill
More informationSponsor / Company: Sanofi Drug substance(s): insulin glargine (HOE901) According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationSensor-augmented pump systems provide insulin delivery
DIABETES TECHNOLOGY & THERAPEUTICS Volume 18, Number 10, 2016 Mary Ann Liebert, Inc. DOI: 10.1089/dia.2016.0216 ORIGINAL ARTICLE Effectiveness of Automated Insulin Management Features of the MiniMed c
More informationInfluence of overweight and obesity on the diabetes in the world on adult people using spatial regression
International Journal of Advances in Intelligent Informatics ISSN: 2442-6571 149 Influence of overweight and obesity on the diabetes in the world on adult people using spatial regression Tuti Purwaningsih
More informationSupplementary Figure 1. Blood glucose and insulin levels in mice during 4-day infusion.
Supplementary Figure 1. Blood glucose and insulin levels in mice during 4-day infusion. (A-B) WT and HT mice infused with saline or glucose had overlapping achieved blood glucose and insulin levels, necessitating
More informationBAPTIST HEALTH SCHOOL OF NURSING NSG 3026A: CHILDREN S HEALTH
J 1 BAPTIST HEALTH SCHOOL OF NURSING NSG 3026A: CHILDREN S HEALTH NURSING MANAGEMENT OF ENDOCRINE DYSFUNCTION: THEORETICAL SKILLS and KNOWLEDGE, SCIENTIFIC PRINCIPLES, CRITICAL THINKING, HEALTHCARE PROMOTION,
More informationREPORT INTERPRETATION
REPORT INTERPRETATION: Interpreting ipro Professional Continuous Glucose Monitoring (CGM) Reports and Making Therapy Adjustments TARGET AUDIENCE The audience for this section is physicians, mid-level practitioners,
More informationBedtime-to-Morning Glucose Difference and iglarlixi in Type 2 Diabetes: Post Hoc Analysis of LixiLan-L
Diabetes Ther (2018) 9:2155 2162 https://doi.org/10.1007/s13300-018-0507-0 BRIEF REPORT Bedtime-to-Morning Glucose Difference and iglarlixi in Type 2 Diabetes: Post Hoc Analysis of LixiLan-L Ariel Zisman.
More informationnocturnal hypoglycemia percentage of Hispanics in the insulin glargine than NPH during forced patients who previously This study excluded
Clinical Trial Design/ Primary Objective Insulin glargine Treat-to-Target Trial, Riddle et al., 2003 (23) AT.LANTUS trial, Davies et al., 2005 (24) INSIGHT trial, Gerstein et al., 2006 (25) multicenter,
More informationThe next five years in diabetes technology: closed-loop systems
The next five years in diabetes technology: closed-loop systems J. H. (Hans) DeVries Academic Medical Center at the University of Amsterd, the Netherlands Keystone, CO, 19 July 2013 Disclosure AP@home,
More informationJournal Club ICU
Journal Club 2018.9.4 ICU Crit Care Med. 2018 Aug;46(8):1224-1229 Introduction Stress hyperglycemia SH SH >124 mg/dl or >200 mg/dl Lancet 2009;373:1798. stress hyperglycemia Lancet 2009;373:1798. SH Critical
More informationLessons Learned: Interdisciplinary collaboration to reduce hypoglycemic events
Lessons Learned: Interdisciplinary collaboration to reduce hypoglycemic events Ryan ull, Pharm.., BCPS ssistant Professor of Pharmacy Practice Creighton niversity School of Pharmacy legent Health Lakeside
More informationJanice Lazear, DNP, FNP-C, CDE DIAGNOSIS AND CLASSIFICATION OF DIABETES
Janice Lazear, DNP, FNP-C, CDE DIAGNOSIS AND CLASSIFICATION OF DIABETES Objectives u At conclusion of the lecture the participant will be able to: 1. Differentiate between the classifications of diabetes
More informationSupplementary Data. Formula S1. Calculation of IG fluctuation from continuous glucose monitoring profiles Z T 1 T
Supplementary Data Formula S1. Calculation of IG fluctuation from continuous glucose monitoring profiles 1 T Z T O jig(t) IGjdt IG, interstitial glucose; IG(t), IG value at time t; IG, mean IG from the
More information6/10/2016. Hui-Chun Hsu
Hui-Chun Hsu PhD, RN, CDE Chief, Department of Diabetes Management Lee s Endocrinology Clinic Pingtung, Taiwan Disclosure to Participants Conflict of Interest (COI) and Financial Relationship Disclosures:
More informationQ99: At what plasma glucose level would glycosuria be expected? Q101: What is the cause of polydipsia in the hypoglycemia?
Q99: At what plasma glucose level would glycosuria be expected? Q100: What is the cause of polyemia in hyperglycemia? Q101: What is the cause of polydipsia in the hypoglycemia? Q102: What is the effect
More informationA toolbox to improve algorithms for insulin-dosing decision support
548 A toolbox to improve algorithms for insulin-dosing decision support K. Donsa 1 ; P. Beck 1 ; J. Plank 2 ; L. Schaupp 2 ; J. K. Mader 2 ; T. Truskaller 1 ; B. Tschapeller 1 ; B. Höll 1 ; S. Spat 1 ;
More informationChapter 37: Exercise Prescription in Patients with Diabetes
Chapter 37: Exercise Prescription in Patients with Diabetes American College of Sports Medicine. (2010). ACSM's resource manual for guidelines for exercise testing and prescription (6th ed.). New York:
More informationHypoglycemia a barrier to normoglycemia Are long acting analogues and pumps the answer to the barrier??
Hypoglycemia a barrier to normoglycemia Are long acting analogues and pumps the answer to the barrier?? Moshe Phillip Institute of Endocrinology and Diabetes National Center of Childhood Diabetes Schneider
More informationNon-insulin treatment in Type 1 DM Sang Yong Kim
Non-insulin treatment in Type 1 DM Sang Yong Kim Chosun University Hospital Conflict of interest disclosure None Committee of Scientific Affairs Committee of Scientific Affairs Insulin therapy is the mainstay
More informationOneTouch Reveal Web Application. User Manual for Healthcare Professionals Instructions for Use
OneTouch Reveal Web Application User Manual for Healthcare Professionals Instructions for Use Contents 2 Contents Chapter 1: Introduction...4 Product Overview...4 Intended Use...4 System Requirements...
More informationESPEN Congress Madrid 2018
ESPEN Congress Madrid 2018 Dysglycaemia In Acute Patients With Nutritional Therapy Mechanisms And Consequences Of Dysglycaemia In Patients Receiving Nutritional Therapy M. León- Sanz (ES) Mechanisms and
More informationDeepika Reddy MD Department of Endocrinology
Deepika Reddy MD Department of Endocrinology Management of hyperglycemic crisis Review need for inpatient glycemic control Brief overview of relevant trials Case based review of diabetes management strategies/review
More informationGoals & Objectives. Diabetes Mellitus
Rudy R. Navarro, M.D., CAQSM Department of Family & Community Medicine UT Health Science Center at San Antonio Goals & Objectives Understand the patterns of glucose utilization during exercise and sporting
More informationContinuous Glucose Monitoring (CGM)
Continuous Glucose Monitoring (CGM) Background Info A1c Average glucose levels over previous 2-3 months Currently remains gold standard for determining control Indicator of risk for development of complications
More informationDiscrete Mean Amplitude of Glycemic Excursion (MAGE) Measurement on Diabetics with Spline Interpolation Method
International Journal on Electrical Engineering and Informatics - Volume 10, Number 2, June 2018 Discrete Mean Amplitude of Glycemic Excursion (MAGE) Measurement on Diabetics with Spline Interpolation
More informationbivariate analysis: The statistical analysis of the relationship between two variables.
bivariate analysis: The statistical analysis of the relationship between two variables. cell frequency: The number of cases in a cell of a cross-tabulation (contingency table). chi-square (χ 2 ) test for
More informationPREVALENCE AND EXTENT OF GLYCEMIC EXCURSIONS IN WELL- CONTROLLED PATIENTS WITH TYPE 2 DIABETES MELLITUS USING CONTINUOUS GLUCOSE-MONITORING SYSTEM
66 PREVALENCE AND EXTENT OF GLYCEMIC EXCURSIONS IN WELL- CONTROLLED PATIENTS WITH TYPE 2 DIABETES MELLITUS USING CONTINUOUS GLUCOSE-MONITORING SYSTEM SHOKOUFEH BONAKDARAN, REZA RAJABIAN ABSTRACT BACKGROUND:
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationDiabetes Technology Continuous Subcutaneous Insulin Infusion Therapy And Continuous Glucose Monitoring In Adults: An Endocrine Society Clinical
Diabetes Technology Continuous Subcutaneous Insulin Infusion Therapy And Continuous Glucose Monitoring In Adults: An Endocrine Society Clinical Practice Guideline Task Force Members Anne Peters, MD (Chair)
More informationSimone Del Favero, PhD, Andrea Facchinetti, PhD, Giovanni Sparacino, PhD, and Claudio Cobelli, PhD
DIA-2016-0413-ver9-Favero_3P.3d 03//17 12:40pm Page 1 DIABETES TECHNOLOGY & THERAPEUTICS Volume 19, Number 4, 2017 ª Mary Ann Liebert, Inc. DOI:.89/dia.2016.0413 ORIGINAL ARTICLE Retrofitting Real-Life
More informationIs Intense Glycemic Control Really Better?
University of Wyoming Wyoming Scholars Repository Honors Theses AY 16/17 Undergraduate Honors Theses Spring 5-12-2017 Is Intense Glycemic Control Really Better? Cierra W. Schutzman University of Wyoming,
More informationEnsuring Safe Physical Activity in Children and Adolescents With Type 1 Diabetes
Ensuring Safe Physical Activity in Children and Adolescents With Type 1 Diabetes FACULTY ADVISOR Lori Laffel, MD, MPH Professor, Pediatrics Harvard Medical School Chief, Pediatric, Adolescent and Young
More informationEstimation of Blood Glucose level. Friday, March 7, 14
Estimation of Blood Glucose level Importance Diagnosis and treatment of carbohydrate metabolism disorders Monitor the effectivity and response to an ongoing treatment procedure Control mechanism Insulin
More informationStructured Association Advanced Topics in Computa8onal Genomics
Structured Association 02-715 Advanced Topics in Computa8onal Genomics Structured Association Lasso ACGTTTTACTGTACAATT Gflasso (Kim & Xing, 2009) ACGTTTTACTGTACAATT Greater power Fewer false posi2ves Phenome
More informationCorrect Site Rotation
Injection Techniques Questionnaire (ITQ) WorldWide Results 2014-2015 Correct Site Rotation BACKGROUND Correct Rotation = at least 1 cm between successive injections Lipohypertrophy and Observed Correct
More informationCARBOHYDRATE METABOLISM Disorders
CARBOHYDRATE METABOLISM Disorders molecular formula C12H22O11 Major index which describes metabolism of carbohydrates, is a sugar level in blood. In healthy people it is 4,4-6,6 mmol/l (70-110 mg/dl)
More informationWelcome to CareLink Pro
Reference Guide Welcome to CareLink Pro This guide was developed to serve as a reference for obtaining patient data and reviewing CareLink Pro reports. Getting Started with CareLink Pro Adding New Patients
More informationParameter Estimation of Cognitive Attributes using the Crossed Random- Effects Linear Logistic Test Model with PROC GLIMMIX
Paper 1766-2014 Parameter Estimation of Cognitive Attributes using the Crossed Random- Effects Linear Logistic Test Model with PROC GLIMMIX ABSTRACT Chunhua Cao, Yan Wang, Yi-Hsin Chen, Isaac Y. Li University
More informationThe Diamond Study: Continuous Glucose Monitoring In Patients on Mulitple Daily Insulin Injections
8/5/217 The Diamond Study: Continuous Glucose Monitoring In Patients on Mulitple Daily Insulin Injections Richard M. Bergenstal, MD Executive Director International Diabetes Center at Park Nicollet Minneapolis,
More informationInsulin Initiation and Intensification. Disclosure. Objectives
Insulin Initiation and Intensification Neil Skolnik, M.D. Associate Director Family Medicine Residency Program Abington Memorial Hospital Professor of Family and Community Medicine Temple University School
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Stewart ZA, Wilinska ME, Hartnell S, et al. Closed-loop insulin
More informationDiabetes Mellitus Type 2 Evidence-Based Drivers
This module is supported by an unrestricted educational grant by Aventis Pharmaceuticals Education Center. Copyright 2003 1 Diabetes Mellitus Type 2 Evidence-Based Drivers Driver One: Reducing blood glucose
More informationPhysical Activity/Exercise Prescription with Diabetes
Physical Activity/Exercise Prescription with Diabetes B R AD H I NTERMEYER C E P A C SM S A NFORD H E ALTH C A RDIAC R E H AB A N D D I ABE TES E XE RCISE The adoption and maintenance of physical activity
More informationNormal glucose values are associated with a lower risk of mortality in hospitalized patients
Diabetes Care Publish Ahead of Print, published online August Hyperglycemia 20, 2008 in hospital Normal glucose values are associated with a lower risk of mortality in hospitalized patients Alberto Bruno
More informationSerum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic
Supplementary Information The title of the manuscript Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic stroke Xin-Wei He 1, Wei-Ling Li 1, Cai Li
More informationInsulin Prior Authorization with optional Quantity Limit Program Summary
Insulin Prior Authorization with optional Quantity Limit Program Summary 1-13,16-19, 20 FDA LABELED INDICATIONS Rapid-Acting Insulins Humalog (insulin lispro) NovoLog (insulin aspart) Apidra (insulin glulisine)
More informationInternational Journal on Future Revolution in Computer Science & Communication Engineering ISSN: Volume: 4 Issue:
Application of the Variance Function of the Difference Between two estimated responses in regulating Blood Sugar Level in a Diabetic patient using Herbal Formula Karanjah Anthony N. School of Science Maasai
More information4.2a Composition of Enteral Nutrition: (Carbohydrate/fat): High fat/low CHO March 2013
4.2a Composition of Enteral Nutrition: (Carbohydrate/fat): March 203 There were no new randomized controlled trials since the 2009 update and hence there are no changes to the following Summary of Evidence.
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Baidal DA, Ricordi C, Berman DM, et al. Bioengineering of an
More informationHyperglycemia Procedure: Management and Treatment Adult Patients
Approved by: Chief Operating Officer; and Chief Medical Officer Hyperglycemia Procedure: Management and Treatment Corporate Policy & Procedures Manual Number: VII-B-465 Date Approved January 23, 2018 Date
More informationAppendix 3: Definition of the types of missingness and terminology used by each paper to
Appendix 3: Definition of the types of missingness and terminology used by each paper to describe the different reasons for missing participant data, with specific terms underlined. Definitions Missing
More informationGLUCOSE CONTROL IN TYPE I DIABETIC PATIENTS: A VOLTERRA MODEL BASED APPROACH. Justin D. Rubb and Robert S. Parker
GLUCOSE CONTROL IN TYPE I DIABETIC PATIENTS: A VOLTERRA MODEL BASED APPROACH Justin D. Rubb and Robert S. Parker Department of Chemical and Petroleum Engineering University of Pittsburgh Pittsburgh, PA
More informationNOTE: The first appearance of terms in bold in the body of this document (except titles) are defined terms please refer to the Definitions section.
TITLE TREATMENT OF HYPERGLYCEMIA - ADULT SCOPE Provincial: Acute Care APPROVAL AUTHORITY Clinical Operations Executive Committee SPONSOR Diabetes, Obesity & Nutrition Strategic Clinical Network PARENT
More informationDiabetes Care 34: , 2011
Clinical Care/Education/Nutrition/Psychosocial Research O R I G I N A L A R T I C L E Use of Continuous Glucose Monitoring in Subjects With Type 1 Diabetes on Multiple Daily Injections Versus Continuous
More informationDiabetes Mellitus in Older Adults. Presenter Disclosure Information
Diabetes Mellitus in Older Adults Medha Munshi, M.D. Joslin Diabetes Center Beth Israel Deaconess Medical Center Harvard Medical School Presenter Disclosure Information Medha Munshi Research grant from
More informationVIRTUAL PATIENTS DERIVED FROM THE
VIRTUAL PATIENTS DERIVED FROM THE CARELINK DATABASE Benyamin Grosman PhD Senior Principle Scientist Medtronic Diabetes WHY VIRTUAL PATIENT MODELING? Reduce the cost of clinical trials Use models in conjunction
More informationEmergencyKT: New Onset Diabetes, Non-DKA Definition: ED patient with newly discovered hyperglycemia, >200 mg %
EmergencyKT: New Onset, Non-DKA Definition: ED patient with newly discovered hyperglycemia, >200 mg % Obtain: CBCD EP1 VBG Serum Ketone Hemoglobin A1c (for follow up) UA β-hcg (female at risk for pregnancy)
More informationDiabetic Equipment and Supplies
Diabetic Equipment and Supplies Chapter.1 Enrollment..................................................................... -2.2 Benefits, Limitations, and Authorization Requirements...........................
More informationEfficacy and Safety of Initial Combination Therapy in Treatment-Naïve Type 2 Diabetes Patients: A Systematic Review and Meta-analysis
Diabetes Ther (2018) 9:1995 2014 https://doi.org/10.1007/s13300-018-0493-2 ORIGINAL RESEARCH Efficacy and Safety of Initial Combination Therapy in Treatment-Naïve Type 2 Diabetes Patients: A Systematic
More informationDiabetes Update: Intensifying Insulin Therapy Nuts, Bolts and Other Items
Diabetes Update: Intensifying Insulin Therapy Nuts, Bolts and Other Items Hayley A. Miller, MD Physician, Internal Medicine, Diabetes and Metabolism, Sandy Clinic, Intermountain Healthcare Objectives:
More informationSociety for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery
Society for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery Girish P. Joshi, MB BS, MD, FFARCSI Anesthesia & Analgesia
More informationContinuous Glucose Monitoring System
Continuous Glucose Monitoring System Policy Number: Original Effective Date: MM.02.003 03/13/2001 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 04/01/2016 Section: DME Place(s)
More informationClinical Study Glycemic Profiles of Healthy Individuals with Low Fasting Plasma Glucose and HbA1c
International Scholarly Research Network ISRN Endocrinology Volume 2011, Article ID 435047, 6 pages doi:10.5402/2011/435047 Clinical Study Glycemic Profiles of Healthy Individuals with Low Fasting Plasma
More informationAcute Glycemic Changes in Brain and Subcutaneous Tissue Measured by Continuous Glucose Monitoring System in Hereditary Hypertriglyceridemic Rat
Physiol. Res. 67: 127-131, 2018 Acute Glycemic Changes in Brain and Subcutaneous Tissue Measured by Continuous Glucose Monitoring System in Hereditary Hypertriglyceridemic Rat M. ŽOUREK 1, P. KYSELOVÁ
More informationAlarge, randomized, controlled trial
Emerging Treatments and Technologies O R I G I N A L A R T I C L E Glucommander A computer-directed intravenous insulin system shown to be safe, simple, and effective in 120,618 h of operation PAUL C.
More informationImplementation of an Interprofessional Team to Prevent Inpatient Hypoglycemic Events. November 12, 2016
Implementation of an Interprofessional Team to Prevent Inpatient Hypoglycemic Events November 12, 2016 St Joseph s Health Fast Facts Founded 1869 by Sisters of St. Francis Patient Volumes (2014) Inpatient
More informationBiochemistry. ENDOCRINE Block Practical Sessions. Editing file M E D I C I N E
HbA NH 2 H 2 O 2 KClO 3 Cl 2 O 7 PO 4 CH2O NAOH KMnO 4 M E D I C I N E KING SAUD UNIVERSITY Co 2 COOH MgCl 2 H 2 O Biochemistry ENDOCRINE Block Practical Sessions Important Doctors slides Extra Information
More informationVANDERBILT UNIVERSITY MEDICAL CENTER MULTIDISCIPLINARY SURGICAL CRITICAL CARE TRAUMA INTENSIVE CARE UNIT GLYCEMIC CONTROL PROTOCOL
VANDERBILT UNIVERSITY MEDICAL CENTER MULTIDISCIPLINARY SURGICAL CRITICAL CARE TRAUMA INTENSIVE CARE UNIT GLYCEMIC CONTROL PROTOCOL Background: For some time, the presence of diabetes and hyperglycemia
More informationContinuous Glucose Monitoring System
Continuous Glucose Monitoring System Policy Number: Original Effective Date: MM.02.003 03/13/2001 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 4/1/2018 Section: DME Place(s)
More informationGLYCEMIC CONTROL SURVEY
GLYCEMIC CONTROL SURVEY Objective: To gain an understanding of the current state of glycemic control (ie, intensive insulin therapy and frequent blood glucose testing) protocol use in hospital inpatients.
More informationReceived for publication 20 October 2006 and accepted in revised form 15 April 2007.
Diabetes Care In Press, published online April 27, 2007 1 Outpatient assessment of KADIS based decision support Received for publication 20 October 2006 and accepted in revised form 15 April 2007. Petra
More informationTuberculosis and Diabetes
Tuberculosis and Diabetes National Web-based Seminar Francis J. Curry National TB Center San Francisco, California December 1, 29 Jane Kelly, M.D. Centers for Disease Control and Prevention jkelly@cdc.gov
More informationHyperglycemia in ACS. Dr. Imhemed Eljazwi
Hyperglycemia in ACS 2012-5-8 Dr. Imhemed Eljazwi Percentage of Population (n = 1181) Prevalence of Hyperglycemia in 181 Cardiac Patients Without Known Diabetes 100% 75% 50% 66% of AMI patients have
More informationImplementation of an Interprofessional Team to Prevent Inpatient Hypoglycemic Events. September 13, 2016
Implementation of an Interprofessional Team to Prevent Inpatient Hypoglycemic Events September 13, 2016 St Joseph s Health Fast Facts Founded 1869 by Sisters of St. Francis Patient Volumes (2014) Inpatient
More informationDevelopment of Optimal Kids Insulin Dosing System Formulas for Young Children with Type 1 Diabetes Mellitus
DIABETES TECHNOLOGY & THERAPEUTICS Volume 14, Number 5, 2012 ª Mary Ann Liebert, Inc. DOI: 10.1089/dia.2011.0184 Development of Optimal Kids Insulin Dosing System Formulas for Young Children with Type
More informationInpatient Management of Diabetes Mellitus. Jessica Garza, Pharm.D. PGY-1 Pharmacotherapy Resident TTUHSC School of Pharmacy
Inpatient Management of Diabetes Mellitus Jessica Garza, Pharm.D. PGY-1 Pharmacotherapy Resident TTUHSC School of Pharmacy 2 Disclosure Jessica Garza does not have any actual or potential conflicts of
More informationCONTROLLO GLICEMICO NEL PAZIENTE CON DMT2: E' SUFFICIENTE HbA1C? Contrario. Antonio Ceriello a,b
CONTROLLO GLICEMICO NEL PAZIENTE CON DMT2: E' SUFFICIENTE HbA1C? Contrario Antonio Ceriello a,b Excessive Glucose Fluctuations With Same A1C Values 400 Mean A1C = 6.7% Glucose Concentration (mg/dl) 300
More information